Department of Medicine, Division of Gastroenterology, Washington University, St Louis School of Medicine, St Louis, Missouri 63110, USA.
Clin Gastroenterol Hepatol. 2012 Sep;10(9):960-8. doi: 10.1016/j.cgh.2012.03.024. Epub 2012 Apr 10.
The enteric microbiota contribute to gastrointestinal health, and their disruption has been associated with many disease states. Some patients consume probiotic products in attempts to manipulate the intestinal microbiota for health benefit. It is important for gastroenterologists to improve their understanding of the mechanisms of probiotics and the evidence that support their use in practice. Clinical trials have assessed the therapeutic effects of probiotic agents for several disorders, including antibiotic- or Clostridium difficile-associated diarrhea, irritable bowel syndrome, and the inflammatory bowel diseases. Although probiotic research is a rapidly evolving field, there are sufficient data to justify a trial of probiotics for treatment or prevention of some of these conditions. However, the capacity of probiotics to modify disease symptoms is likely to be modest and varies among probiotic strains-not all probiotics are right for all diseases. The current review provides condition-specific rationale for using probiotic therapy and literature-based recommendations.
肠内微生物群有助于胃肠道健康,其紊乱与许多疾病状态有关。一些患者服用益生菌产品,试图通过操纵肠道微生物群来促进健康。对于胃肠病学家来说,提高他们对益生菌作用机制的理解以及支持其在实践中应用的证据非常重要。临床试验已经评估了益生菌制剂在多种疾病中的治疗效果,包括抗生素或艰难梭菌相关性腹泻、肠易激综合征和炎症性肠病。虽然益生菌研究是一个快速发展的领域,但有足够的数据支持益生菌治疗或预防其中一些疾病的应用。然而,益生菌改变疾病症状的能力可能是适度的,并且在益生菌菌株之间存在差异——并非所有益生菌都适用于所有疾病。本综述提供了针对特定疾病使用益生菌治疗的具体理由和基于文献的推荐建议。